Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 57, Issue 11, 2012, Pages 2917-2923

  Jin, Young Joo ^a   Chung, Young Hwa ^a   Kim, Jeong A ^a   Park, Won Hyung ^a   Lee, Danbi ^a   Seo, Dong Dae ^b   Ryu, Soo Hyung ^b   Jang, Myoung Kuk ^c   Yu, Eunsil ^a   Lee, Young Joo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Metastatic tumor antigen 1

Indexed keywords

ALPHA FETOPROTEIN; METASTATIC TUMOR ANTIGEN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER SURGERY; CHILD TURCOTTE PUGH SCORE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DIAGNOSTIC IMAGING; FEMALE; HEPATITIS B VIRUS; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

EID: 84871616761     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2296-z     Document Type: Article

References (33)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34.
3. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet. 1981;2:1129-1133.
4. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193-199.
5. Qu LS, Jin F, Huang XW, et al. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2010;14:1111-1120.
6. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63-70.
7. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
8. Kokudo N, Ishizawa T, Hasegawa K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908-1916.
9. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.
10. Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008;47:929-936.
11. Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of mta family members in human cancers. Semin Oncol. 2003;30:30-37.
12. Sasaki H, Moriyama S, Nakashima Y, et al. Expression of the MTA-1 mRNA in advanced lung cancer. Lung Cancer. 2002;35:149-154.
13. Hofer MD, Kuefer R, Varambally S, et al. The role of metastasisassociated protein 1 in prostate cancer progression. Cancer Res. 2004;64:825-829.
14. Hofer MD, Tapia C, Browne TJ, et al. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med. 2006;130:989-996.
15. Toh Y, Oki E, Oda S, et al. Overexpression of the MTA-1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 1997;74:459-463.
16. Moon HE, Cheon H, Chun KH, et al. Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1 alpha. Oncol Rep. 2006;16:929-935.
17. Chan DA, Sutphin PD, Yen SE, et al. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol. 2005;25:6415-6426.
18. Moon WS, Chang K, Tarnawski AS. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Hum Pathol. 2004;35:424-429.
19. Semenza GL, Nejfelt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 30 to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991;88: 5680-5684.
20. Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 2006;25:1231-1241.
21. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018-1022.
22. Di Lelio A, Cestari C, Lomazzi A, et al. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 1989;172:389-392.
23. Katyal S, Oliver JH III, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216:698-703.
24. Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer. 1990;66:2174-2179.
25. El-Assal ON, Yamanoi A, Soda Y, et al. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery. 1997;122:571-577.
26. Kim JH, Choi MS, Lee H, et al. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006;21:588-594.
27. Chedid A, Ryan LM, Dayal Y, et al. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med. 1999;123:524-528.
28. Chen CH, Chang TT, Cheng KS, et al. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int. 2006;26:766-773.
29. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000;32:233-238.
30. Farinati F, Sergio A, Giacomin A, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 2009;21:1212-1218.
31. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463.
32. Tralhao JG, Kayal S, Dagher I, et al. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology. 2007;54:1200-1206.
33. Kubo S, Tanaka H, Shuto T, et al. Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. Surg Today. 2005;35:216-222.